JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.74 -0.8

Buy Sell

Overview

Share price change

24h

Current

Min

3.7

Max

3.81

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+287.07% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	24M 252M
Previous open	4.54
Previous close	3.74

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 kwi 2026, 23:15 UTC

Major News Events

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 kwi 2026, 23:08 UTC

Earnings

Major Market Movers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 kwi 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 kwi 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 kwi 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 kwi 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 kwi 2026, 22:10 UTC

Earnings

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 kwi 2026, 21:56 UTC

Earnings

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 kwi 2026, 21:44 UTC

Earnings

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 kwi 2026, 21:43 UTC

Earnings

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 kwi 2026, 20:39 UTC

Earnings

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

287.07% upside

12 Months Forecast

Average 14.67 USD 287.07%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.